Anavex Life Sciences Corp (AVXL)

[falconer66a]

It’s Not Just Anavex 2-73

I don't know a bit about biochemistry and cellular biology.
Could you elaborate on "The future of Anavex Life Sciences Corp is not just Anavex 2-73, by any means" please.

There seems to be a presumption that the future of Anavex rests solely upon clinical trial success against Rett syndrome, Parkinson’s disease, or Alzheimer’s disease. The drug is currently being clinically tested in humans for all three of these. Demonstration of therapeutic efficacy for any one of these will assure regulatory approval of sales of the drug. Anavex Life Sciences Corp will then be a revenue-generating entity.

I’ve scrutinized a host of papers revealing efficacies against all three of these diseases in transgenic murines (lab rodents with human disease genes). In every case, useful symptomatic suppression or regression was demonstrated. I fully expect that each of the three new human trials will reveal levels of symptomatic improvement sufficient to cause regulatory approval. For that, in each of the three cases, the bar to cross, the existing standard of care, the existing treatment drugs, fail to provide any significant treatments for the three diseases. Anavex 2-73 is extremely likely to work for at least one of the three diseases, if not all three. Very little existing competition.

And, as the existing human experiences with Anavex 2-73 shows, adverse events (side effects) are infrequent and universally mild and inconsequential. That’s seldom the case with drugs acting on the central nervous system. Anavex drugs are unique in that regard.

And such will be the case with the other in-the-pipeline Anavex drugs; particularly Anavex 3-71. Murine data show it to be even more powerful than Anavex 2-73 in treating various CNS conditions.

The fully-developed future of Anavex Life Sciences Corp may not be with Anavex 2-73. Anavex insiders have seen all of the murine test data and know better than anyone that Anavex 3-71 yields better treatment results. Should (well, when) Anavex 2-73 gain(s) regulatory approval for sales and therapeutic use, I can see the company then quickly moving Anavex 3-71 into new, expanded clinical trials for a number of CNS conditions.

Ten years from now, with annual international revenues in the hundreds of millions of dollars (well, billions), the lead drug of the company may very well be Anavex 3-71.

A few other sigma-1 receptor agonists in the corporate pipeline may be treating any number of other diseases and conditions.